Kirilys Therapeutics to Present Preclinical Profile for KRLS-017, a reversible inhibitor of CDK7 for Oncolog
First presentation of full preclinical profile of KRLS-017, a potentially best in class reversible small molecule inhibitor of Cyclin Dependent Kinase 7 (CDK7) San Francisco, CA, December 11, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, plans to present a detailed preclinical profile for […]
Kirilys Therapeutics Announces FDA Clearance of IND Application for KRLS-017, a reversible inhibitor of CDK7 for Oncology
Phase 1 clinical study will evaluate the safety, pharmacokinetics, and preliminary efficacy of KRLS-017 in treatment refractory solid tumors San Francisco, CA, April 28, 2023 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, today announced the Food and Drug Administration (FDA) has cleared the Investigational […]
Kirilys Therapeutics Acquires ASN-004, a 5T4-targeting Antibody Drug Conjugate being evaluated in Ph1 Oncology
Ongoing Phase 1 clinical study is evaluating the safety, pharmacokinetics, and preliminary efficacy of ASN-004 in treatment refractory solid tumors San Francisco, CA, September 1, 2022 — Kirilys Therapeutics, Inc., a multi-asset biotechnology company founded by investment firm Catalys Pacific and supported by Lightspeed Venture Partners, completed the acquisition of ASN-004 from Asana Biosciences, Inc. Kirilys plans […]
Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company
SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed a partnership agreement with D2G […]